USPTO Examiner VANHORN ABIGAIL LOUISE - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19083361Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using SameMarch 2025January 2026Allow1011YesNo
18730678METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTSJuly 2024August 2025Allow1320YesNo
18393974ADAPTER FOR USE IN A PLANETARY MIXERDecember 2023April 2025Allow1630NoNo
18501446ADAPTER FOR USE IN A PLANETARY MIXERNovember 2023August 2024Allow920YesNo
18446687LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGSAugust 2023September 2025Allow2510NoNo
18231955PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOFAugust 2023January 2026Abandon2910NoNo
18208658ACTIVATED CARBON PHARMACEUTICAL COMPOSITIONSJune 2023January 2026Allow3110NoNo
18195307PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALEMay 2023November 2025Abandon3110NoNo
18143944IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASEMay 2023March 2026Allow3470YesNo
18140646Topical preparations comprising biodegradable polyalkoxylated polyols polyesterApril 2023September 2025Allow2841YesNo
18295906MEDICAMENT-CONTAINING HOLLOW PARTICLEApril 2023August 2025Abandon2901NoNo
18130771TOPICAL COMPOSITION FOR TREATING DANDRUFF AND SEBORRHEIC DERMATITIS OF A SCALPApril 2023March 2026Abandon3520NoYes
18121883METHODS FOR ADMINISTERING ARIPIPRAZOLEMarch 2023June 2025Abandon2710NoNo
18177011METHODS FOR FIXING HAIR AND SKINMarch 2023February 2026Abandon3551YesYes
18108368PERGULARIA TOMENTOSA SILVER NANOPARTICLESFebruary 2023April 2025Abandon2641NoNo
18156432SOLID LIPID NANOPARTICLE FOR INTRACELLULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD FOR PRODUCTION THE SAMEJanuary 2023May 2025Allow2711YesNo
18096869COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESIONJanuary 2023November 2025Abandon3421NoNo
18092517COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENTJanuary 2023September 2024Allow2031YesNo
18003609METHOD FOR DIAGNOSING DOWN'S SYNDROME BY USING DOWN'S SYNDROME-SPECIFIC EPIGENETIC MARKERDecember 2022February 2026Abandon3841YesNo
18067541FORTIFIED MICRONUTRIENT SALT FORMULATIONSDecember 2022May 2025Abandon2911NoNo
18076023IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASEDecember 2022March 2026Allow3960YesNo
18058513MODIFIED GENE VACCINES AGAINST AVIAN CORONAVIRUSES AND METHODS OF USING THE SAMENovember 2022March 2026Allow4010YesNo
17992783CARBON DOTS FOR DIAGNOSTIC ANALYSIS AND DRUG DELIVERYNovember 2022June 2025Abandon3011NoNo
18053865RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIANovember 2022June 2025Allow3131NoNo
17915569NUCLEIC ACIDS ENCODING HUMAN FUS PROTEIN AND USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)September 2022January 2026Abandon4001NoNo
17933937AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEMSeptember 2022February 2026Allow4110YesNo
17941675METHODS FOR FIXING HAIR AND SKINSeptember 2022December 2024Allow2821YesNo
17884187METHODS AND CONTROL COMPOSITIONS FOR A QUANTITATIVE POLYMERASE CHAIN REACTIONAugust 2022December 2025Allow4020NoNo
17816456BIODEGRADABLE HYDROGEL AND METHODS FOR USE THEREOFAugust 2022July 2025Abandon3631YesNo
17854139COLLAGEN-BASED THERAPEUTIC DELIVERY SYSTEMSJune 2022December 2024Allow2921YesNo
17836067METHODS FOR MAKING COMPOSITIONS FOR PULMONARY ADMINISTRATIONJune 2022October 2024Allow2811NoNo
17771808OVERLAPPING THERAPEUTIC STRATEGIES FOR CYSTINOSIS TREATMENT AND COSMETIC SKIN DARKENINGApril 2022January 2026Abandon4501NoNo
17640764METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTIONMarch 2022November 2025Abandon4411NoNo
17680295COMPOSITIONS AND METHODS FOR INHIBITING TCF/LEF TRANSCRIPTIONAL ACTIVITYFebruary 2022February 2025Abandon3511NoNo
17675674DRUG TREATMENT AND BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTIONFebruary 2022August 2025Abandon4221NoNo
17633478METHOD FOR PRODUCING NUCLEIC ACID MOLECULEFebruary 2022December 2025Abandon4701NoNo
17591485LIPOPOLYSACCHARIDE (LPS) APTAMERS AND ASSOCIATED METHODSFebruary 2022December 2025Allow4711YesNo
17589223NANODRUG PARTICLES, THE USE THEREOF, AND PREPARATION METHOD THEREOFJanuary 2022September 2025Abandon4331NoNo
17587743BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOFJanuary 2022December 2025Abandon4710NoNo
17631216COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLSJanuary 2022December 2025Abandon4601NoNo
17564399METHODS FOR MAKING ANTIFOULING MATERIALSDecember 2021December 2024Allow3631YesNo
17564405ANTIFOULING MATERIALSDecember 2021December 2025Abandon4830YesNo
17620879A PHARMACEUTICAL COMPOSITION OF S1PR MODULATORSDecember 2021March 2025Allow3900NoNo
17644986COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASESDecember 2021December 2025Abandon4801NoNo
17616760COMPOSITIONS AND METHODS RELATING TO ERYTHROCYTES WITH ADHERED PARTICLESDecember 2021February 2026Allow5021YesYes
17616800COMPOSITIONS AND METHODS FOR IMPROVING PLANT HEALTH AND CONTROLLING PLANT DISEASEDecember 2021May 2025Abandon4101NoNo
17542112METHODS FOR TREATING RELAXED HAIRDecember 2021June 2024Allow3020YesNo
17538733ENHANCED PERFORMANCE SOLUTION FOR TISSUE GRAFTSNovember 2021March 2025Abandon3941NoNo
17615152SOLID DISPERSION AND PREPARATION METHOD THEREFORNovember 2021August 2025Abandon4541NoNo
17595584NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USENovember 2021October 2025Allow4711YesNo
17595620NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USENovember 2021January 2026Abandon5011NoNo
17612912NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USENovember 2021August 2025Allow4511YesNo
17525521PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID, METHOD FOR MANUFACTURING PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID, AND PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID MANUFACTURING APPARATUSNovember 2021December 2024Allow3740YesNo
17482143HYDROGEL-ENCAPSULATED BETA CELLS, BETA-CELL ENCAPSULATION PROCESS, AND USES THEREOFSeptember 2021December 2024Abandon3921YesNo
17439159NOVEL NUCLEIC ACID MODIFIERSSeptember 2021November 2025Abandon5001NoNo
17473676METHODS OF TREATING MENTAL DISORDERSSeptember 2021December 2025Abandon5111NoNo
17471878MIXED MATERIAL IMPLANTS INCORPORATING ADDITIVESSeptember 2021November 2024Abandon3821NoNo
17406609KERATIN TREATMENT FORMULATIONS AND METHODSAugust 2021April 2025Abandon4321NoYes
17365361MODIFIED NUCLEOTIDES AND USES THEREOFJuly 2021September 2025Allow5112NoNo
17362397COLOR COATINGS WITH DOWNSTREAM FEATURESJune 2021March 2025Abandon4521NoNo
17359137AUXIN HERBICIDE AND L-GLUFOSINATE MIXTURESJune 2021July 2025Abandon4941NoNo
17358929SYNTHETIC ANTIMICROBIAL MINERAL COMPOSITIONS, METHODS OF MAKING AND USING SAMEJune 2021August 2024Allow3821NoNo
17357119DISSOLVABLE SOLID FIBROUS ARTICLES CONTAINING ANIONIC SURFACTANTSJune 2021June 2025Abandon4751NoNo
17340405OSTEOGENIC BIOMATERIALJune 2021October 2024Allow4031YesNo
17311211REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLSJune 2021March 2026Abandon5821YesNo
17298326USE OF CATIONIC HYDROXYALKYL GUARS FOR MICROORGANISMS GROWTHMay 2021July 2025Allow5030YesNo
17317335COMPOSITIONS OF POLYMERIC MICRODEVICES AND METHODS OF USE THEREOF IN CANCER IMMUNOTHERAPYMay 2021April 2025Allow4741YesNo
17243113AEROSOL SPRAYER FOR INSECT PEST MATING DISRUPTIONApril 2021October 2024Allow4220NoNo
17223641DRUG RELEASING COATINGS FOR MEDICAL DEVICESApril 2021December 2024Abandon4431NoNo
17281014INJECTABLE HYDROGELS FOR CONTROLLED RELEASE OF IMMUNOMODULATORY COMPOUNDSMarch 2021June 2025Allow5021YesNo
17256387Hyaluronic Acid-Based Zwitterionic Polymer Brush, Preparation Method Thereof, and Use ThereofDecember 2020January 2025Allow4921YesNo
17105587Composition of corneal implantation, and the use and preparation method thereofNovember 2020October 2024Abandon4631NoNo
17054137NOVEL CROP NUTRITION AND FORTIFICATION COMPOSITIONNovember 2020July 2025Allow5631YesNo
17049776TRANSITION METAL ORGANIC FRAMEWORK HAVING ANTIBACTERIAL PROPERTIESOctober 2020October 2025Abandon6031NoNo
17035339COMPOSITIONS AND METHODS FOR TARGETING CELLSSeptember 2020July 2024Allow4641YesNo
17024755Horticulture AdditiveSeptember 2020May 2025Abandon5541NoNo
16999841RADIOPAQUE MULTI-ARMED POLYMERS AND COMPOSITIONS, SYSTEMS AND METHODS PERTAINING TO THE SAMEAugust 2020January 2025Allow5341YesNo
15733436NOVEL ANTHRANILAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAMEJuly 2020October 2024Allow5121YesNo
16920341PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANESJuly 2020August 2024Allow5041YesNo
16447716TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTSJune 2019October 2024Abandon6061NoNo
16427560RESIDENT ARTICLES FOR GRAM-LEVEL DOSINGMay 2019April 2025Allow6060YesNo
15769710CANCER VACCINESApril 2018November 2025Allow6051YesNo
15838977METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTIONDecember 2017April 2019Allow1611YesNo
15570276ANTIBACTERIAL NANOFIBRESOctober 2017July 2020Abandon3391NoNo
15542793COSMETIC COMPOSITION FOR ORAL ADMINISTRATION FOR REINFORCING THE SKIN BARRIERJuly 2017September 2018Allow1430YesNo
15582076HAIR-TREATMENT COMPOSITIONS COMPRISING A POLYURETHANE LATEX POLYMER AND CATIONIC COMPOUNDApril 2017May 2025Allow60101YesYes
15492146METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTIONApril 2017April 2019Allow2421YesNo
15483006ANTIBACTERIAL SPECTACLE PART AND ANTIBACTERIAL TREAMENT METHODApril 2017July 2018Allow1521YesNo
153938506-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDESDecember 2016May 2018Allow1621NoNo
15322776Antitumor Composition Based on Hyaluronic Acid and Inorganic Nanoparticles, Method of Preparation Thereof and Use ThereofDecember 2016February 2020Allow3741YesNo
15361426CRYSTALLINE COATING AND RELEASE OF BIOACTIVE AGENTSNovember 2016July 2018Allow2021YesNo
15079171METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITIONMarch 2016January 2018Allow2230YesNo
14919962SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOFOctober 2015August 2017Allow2210YesNo
14776827METHODS OF IDENTIFICATION AND USE OF NEMATICIDE COMPOUNDSSeptember 2015September 2019Allow4821YesNo
14756288Acne formulation having stabilized ascorbic acid and other activesAugust 2015May 2017Allow2110YesNo
14762286AGROCHEMICAL COMPOSITION, METHOD FOR ITS PREPARATION AND USE THEREOFJuly 2015September 2019Allow5061YesNo
14742936PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAMEJune 2015June 2017Allow2411YesNo
14702843Method for Oxygen Treatment of Intact SkinMay 2015October 2016Allow1710YesNo
14667826ABUSE DETERRENT IMMEDIATE RELEASE BIPHASIC MATRIX SOLID DOSAGE FORMMarch 2015December 2016Allow2120YesNo
14427846A SOFT GELATIN ENCAPSULATED PHARMACEUTICAL COMPOSITION OF CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID IN FREE ACID FORM AND CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID IN FREE ACID FORMMarch 2015March 2019Allow4851YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VANHORN, ABIGAIL LOUISE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
4
(66.7%)
Examiner Reversed
2
(33.3%)
Reversal Percentile
49.2%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
8
(29.6%)
Not Allowed After Appeal Filing
19
(70.4%)
Filing Benefit Percentile
44.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner VANHORN, ABIGAIL LOUISE - Prosecution Strategy Guide

Executive Summary

Examiner VANHORN, ABIGAIL LOUISE works in Art Unit 1636 and has examined 142 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner VANHORN, ABIGAIL LOUISE's allowance rate of 85.2% places them in the 62% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by VANHORN, ABIGAIL LOUISE receive 3.25 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VANHORN, ABIGAIL LOUISE is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +40.9% benefit to allowance rate for applications examined by VANHORN, ABIGAIL LOUISE. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.8% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.0% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 52.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.9% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.0% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.